Lung Surfactant Activity, Inhibition and Replacement

肺表面活性剂的活性、抑制和替代

• 批准号: 6579778
• 负责人: ROBERT H NOTTER
• 金额: $ 33.86万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-07-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6579778
• 关键词: adsorption; apolipoproteins; biomechanics; biomimetics; biophysics; chromatography; drug design /synthesis /production; infrared spectrometry; inhibitor /antagonist; interferometry; laboratory rat; lung injury; nonhuman therapy evaluation; phospholipids; pneumonia; pulmonary surfactants; respiratory gas transport; surface property; synthetic peptide; viscosity

DESCRIPTION (provided by applicant): This research studies the component-specific molecular biophysics and physiological activity of biological and synthetic pulmonary surfactants. A major goal is to develop new highly active phospholipase-resistant synthetic exogenous surfactants containing novel lipids and peptides for use in the neonatal and acute respiratory distress syndromes (RDS and ARDS). The research also seeks to improve fundamental understanding about surfactant activity and dysfunction. Aims 1 and 2 examine the surface activity, resistance to inhibition, and P-V mechanical effects in lavaged excised rat lungs of synthetic exogenous surfactants containing novel phospholipase-resistant phospholipid analogs plus synthetic peptides or purified apoproteins. Lavaged calf lung surfactant and current animal-derived clinical surfactants are comparative standards. Complementary biophysical methods are used to fully assess surface-active behavior (Wilhelmy balance, pulsating bubble, adsorption, Brewster-angle microscopy, differential scanning calorimetry, FTIR spectroscopy). Materials studied include synthetic di-ether and ether-thio-phosphonolipids and phospholipids, synthetic regional human-sequence SP-B, SP-C, and SP-A peptides, synthetic glycerophospholipids, and specific lipids and apoproteins purified chromatographically from natural surfactant. Biophysical and excised lung studies in Aims 1, 2 are extended in Aim 3, to define the efficacy of the most active exogenous surfactants in reversing surfactant dysfunction, improving gas exchange, and reducing lung injury in rats with ARDS-related gram negative pneumonitis in vivo. Also studied is the formulation of surfactant dispersions with low shear viscosity to enhance their pulmonary delivery and distribution following tracheal instillation. This integrated hierarchy of biophysical and physiological research will advance basic knowledge about surfactant activity and dysfunction, and define new exogenous surfactants with maximal activity, inhibition resistance, and pulmonary delivery for therapeutic applications.

描述（由申请人提供）：本研究研究生物和合成肺表面活性剂的组分特异性分子生物物理学和生理活性。一个主要目标是开发新的高活性磷脂酶抗性合成外源性表面活性剂，含有新的脂质和肽，用于新生儿和急性呼吸窘迫综合征（RDS和ARDS）。这项研究还试图提高对表面活性剂活性和功能障碍的基本认识。目的1和目的2检测含有新型磷脂酶抗性磷脂类似物和合成肽或纯化载脂蛋白的合成外源性表面活性剂在灌洗切除大鼠肺中的表面活性、抗抑制性和P-V机械效应。洗胃小牛肺表面活性剂与目前临床动物源性表面活性剂为比较标准。互补的生物物理方法用于全面评估表面活性行为（威廉平衡，脉动气泡，吸附，布鲁斯特角显微镜，差示扫描量热法，傅里叶红外光谱）。研究的材料包括合成的二醚和醚硫代磷脂和磷脂，合成的区域人类序列SP-B、SP-C和SP-A肽，合成的甘油磷脂，以及从天然表面活性剂中色谱纯化的特定脂质和载脂蛋白。Aims 1,2中的生物物理和切除肺研究在Aims 3中得到扩展，以确定最活跃的外源性表面活性剂在ards相关革兰氏阴性肺炎大鼠体内逆转表面活性剂功能障碍、改善气体交换和减少肺损伤的功效。此外，还研究了低剪切粘度表面活性剂分散体的配方，以增强其在气管灌注后的肺输送和分布。这种生物物理和生理研究的综合层次将推进表面活性剂活性和功能障碍的基础知识，并定义具有最大活性，抑制抗性和肺输送治疗应用的新外源性表面活性剂。